Nanobodies TM targeting amyloid beta as potential therapeutics for Alzheimer's disease

Active and passive immunization strategies targeting amyloid beta are currently being developed as a potential therapy to treat Alzheimer's disease (AD). Both approaches have shown efficacy in animal models, while passive vaccination is expected to be safer in the clinical context. We have explored the use of amyloid beta targeting Nanobodies for passive immunotherapy of AD. Nanobodies are 12-15 kDa protein domains derived from camelid Heavy-Chain antibodies with unique characteristics that offer many advantages over the use of conventional monoclonal antibodies.Peer reviewed: YesNRC publication: Ye